Marshall Wace
ELTX icon

Marshall Wace’s Elicio Therapeutics ELTX Stock Holding History

Marshall Wace’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$797K Sell
74,512
-42,688
-36% -$412K ﹤0.01% 2238
2025
Q4 		$933K Buy
117,200
+30,667
+35% +$278K ﹤0.01% 1965
2025
Q3 		$947K Buy
+86,533
New +$876K ﹤0.01% 1963

Other funds holding ELTX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Marshall Wace's ELTX Position: Q1 2026 in Review

Marshall Wace reduced its Elicio Therapeutics (ELTX) stake by 36% in Q1 2026, selling an estimated $412K and leaving 74,512 shares worth $797K. The position accounts for ﹤0.01% of the portfolio, ranked #2238.

Marshall Wace first reported a position in ELTX in Q3 2025 and has held it in 3 quarters since. The position peaked at $947K in Q3 2025. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

  • Marshall Wace held 74,512 shares of Elicio Therapeutics worth $797K as of Q1 2026.
  • Marshall Wace sold 42,688 Elicio Therapeutics shares in Q1 2026, an estimated $412K.
  • Elicio Therapeutics made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2238 holding.
  • Marshall Wace first reported a position in Elicio Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Marshall Wace's Elicio Therapeutics position peaked at $947K in Q3 2025.
  • 47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.